Since 2021 Biogen has been working cooperatively with the U.S. House Committee on Oversight and Reform and the U.S. House Energy and Commerce Committee regarding their investigations into the launch of Aduhelm, including providing requested information. Today, the Committees released the joint findings of their review. Biogen issued the following statement in response to the report:
Biogen has been committed to researching and developing treatments for Alzheimer’s disease for more than a decade. We have been focused relentlessly on innovation to address this global health challenge, and have adapted to both successes and setbacks.
Biogen stands by the integrity of the actions we have taken.
As stated in the congressional report, an FDA review concluded that, “There is no evidence that these interactions with the sponsor in advance of filing were anything but appropriate in this situation.”
Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm. That process is continuing to inform our work as Biogen introduces new innovative treatments to the market. We will continue to appropriately engage diverse stakeholders at every step, including patients and their families, health care providers, and the scientific community.
We are dedicated to our mission of bringing innovative and transformative treatments to patients with serious and hard-to-treat conditions.